title: Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
abstract: The management of metastatic melanoma has been revolutionized in recent years with the development of both targeted therapy and immunotherapy. Although potentially extending the life expectancy for patients, these therapies also significantly increase the healthcare expenditure. In this paper, we review the monthly costs for drugs approved by the FDA since 2011. Additionally, factors that affect the cost, such as dosing strategies, biomarkers, combination therapies, and political/legislative issues, will be discussed.
authors.affiliation: dgolds8@emory.edu.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Goldstein
authors.forename: Simon B
authors.initials: SB
authors.lastname: Zeichner
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D019468:Disease Management; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005102:Health Expenditures; D006296:Health Services / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000191:economics / Q000379:methods*; D009362:Neoplasm Metastasis; D011787:Quality of Health Care; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor